Here are some key takeaways from the CURE® Educated Patient® Multiple Myeloma Summit.
The CURE® Educated Patient® Multiple Myeloma Summit is a half-day virtual program that features the voices of fellow survivors and experts, providing patients with everything they need to know about the disease, regardless of where they fall in their treatment experience.
From new therapies to clinicians trekking across Mount Kilimanjaro and other mountains alongside patients and their loved ones, here are five things readers may have missed from CURE®’s Educated Patient® Multiple Myeloma Summit.
A t-cell therapy called teclistamab for relapsed/refractory myeloma is currently being investigated, as is the immunomodulary drug, iberdomide, for patients who already received a BCMA-targeted therapy. Other regimens are also on the horizon for 2023 and beyond.
CAR-T cell therapy allows patients with myeloma to have their own cells engineered to fight cancer, while bispecific T-cell engagers (BiTE) therapy helps activate exhausted T cells and amp up the attack against tumors.
Patients with myeloma are living longer than ever before, making long-term management of the disease paramount. A patient, their caregiver, doctor and nurse sat down to discuss when myeloma becomes a chronic disease.
New drugs and multiple-drug combinations present a multitude of treatment options for patients with relapsed or refractory myeloma. However, these treatments aren’t one size fits all, and patients should work with their health care team to determine which therapy is best for them.
Receiving a diagnosis of multiple myeloma can be overwhelming, but new therapies are helping patients achieve remission or disease control and live normal lives.
VIEW MORE: Summits on Demand
For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.